In 2017, nivolumab, a PD-1 inhibitor, was the first Food and Drug Administration (FDA)-approved monoclonal antibody (mAb) for second-line targeted therapy in the treatment of HCC. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.